Epothilone d, production process, and its use as cytostatic as well as phytosanitary agent
3 claims: 2 independent, 1 dependent
- 1Verfahren zur Herstellung von Epothilon D, bei dem man (a) Sorangium cellulosum DSM 6773 in Gegenwart eines Adsorberharzes in an sich bekannter Weise kultiviert, (b) das Adsorberharz von der Kultur abtrennt und mit einem Wasser/Methanol-Gemisch wäscht, (c) das gewaschene Adsorberharz mit Methanol eluiert und das Eluat zu einem Rohextrakt einengt, (d) das gewonnene Konzentrat mit Ethylacetat exrahiert, den Extrakt einengt und zwischen Methanol und Hexan verteilt, (e) die methanolische Phase zu einem Raffinat einengt und das Konzentrat an einer Sephadex-Säule fraktioniert, (f) eine Fraktion mit Stoffwechselprodukten des eingesetzten Mikroorganismus gewinnt, (g) die gewonnene Fraktion an einer C18-Umkehrphase mit einem Methanol/Wasser-Gemisch chromatographiert und in zeitlicher Reihenfolge - nach einer ersten Fraktion mit Epothilon A und - einer zweiten Fraktion mit Epothilon B - eine dritte Fraktion mit einem ersten weiteren Epothilon (Epothilon C) und - eine vierte Fraktion mit einem zweiten weiteren Epothilon (Epothilon D) gewinnt und (h) das Epothilon (Epothilon D) der zweiten weiteren Fraktion isoliert.
- 2Epothilon D der Formel:Epothilon D R = CH 3 und der Summenformel C 27 H 41 NO 5 S, gekennzeichnet durch das 1 H- und 13 C-NMR-Spektrum gemäß Tabelle 1.
- 3Therapeutisches Mittel, insbesondere zum Einsatz als Cytostatikum, bestehend aus einer Verbindung nach Ansprüche 2 oder einer Verbindung nach Ansprüche 2 neben einem oder mehreren üblichen Träger(n) und/oder Verdünnungsmittel(n).
Independent claims3
27 paragraphs, as filed
0001The present invention relates to epothilones D, its preparation and a therapeutic agent.
0002In one embodiment, the invention relates to a process for the preparation of epothilone [D], in which<ol id="ol0001" compact="compact"><li>(a) <i>Sorangium cellulosum</i> DSM 6773 cultivated in the presence of an adsorber resin in a manner known per se;</li><li>(b) the adsorber resin is separated from the culture and washed with a water / methanol mixture,</li><li>(c) the washed adsorber resin eluted with methanol and the eluate is concentrated to a crude extract,</li><li>(d) the concentrate obtained is extracted with ethyl acetate, the extract is concentrated and partitioned between methanol and hexane,</li><li>(e) the methanolic phase is concentrated to a raffinate and the concentrate is fractionated on a Sephadex column,</li><li>(f) a fraction with metabolic products of the microorganism used is obtained,</li><li>(g) the fraction obtained is chromatographed on a C18 reverse phase with a methanol / water mixture and in chronological order<ul id="ul0001" list-style="dash" compact="compact"><li>after a first fraction with epothilone A and</li><li>a second fraction with Epothion B</li><li>a third fraction with a first further epothilone (Epothilon C) and</li><li>a fourth fraction with a second further epothilone (Epothilon D) wins and</li></ul></li><li>(h) the epothilone of the second further fraction (epothilone D) is isolated.</li></ol>
0003The invention further relates to epothilone D of the formula:<chemistry id="chem0001" num="0001"><img file="EP0941227B2_D0001.tif" /></chemistry>Epothilon DR = CH<sub>3</sub>and the empirical formula C<sub>27</sub>H<sub>41</sub>NO<sub>5</sub>S, characterized by the <sup>1</sup>Dog <sup>13</sup>C-NMR spectrum according to Table 1. Epothilon D can be used to prepare the compounds of the following <b>formula 1</b> are used, for their derivatization to the in <patcit id="pcit0001" dnum="WO9719086A"><text>WO-A-97/19 086</text></patcit> described derivatization methods can be referred.<chemistry id="chem0002" num="0002"><img file="EP0941227B2_D0002.tif" /></chemistry>
0004In formula 1 above:<ul id="ul0002" list-style="none" compact="compact"><li>R = H, C<sub>1-4</sub>-Alkyl;</li><li>R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> = H, C<sub>1-6</sub>-Alkyl,</li><li>C.<sub>1-6</sub>Acyl benzoyl,</li><li>C.<sub>1-4</sub>-Trialkylsilyl,</li><li>Benzyl,</li><li>Phenyl,</li><li>C.<sub>1-6</sub>-Alkoxy-,</li><li>C.<sub>6</sub>-Alkyl-, hydroxy- and halogen-substituted benzyl or phenyl;</li></ul>where two of the radicals R<sup>1</sup> to R<sup>5</sup> to the grouping - (CH<sub>2</sub>)<sub>n</sub>- can meet with n = 1 to 6 and the alkyl or acyl groups contained in the radicals are straight-chain or branched radicals; Y and Z are either the same or different and each represents hydrogen, halogen, such as F, Cl, Br or J, pseudohalogen, such as -NCO, -NCS or -N<sub>3</sub>, OH, O- (C<sub>1-6</sub>) Acyl, O- (C<sub>1-6</sub>) Alkyl, O-benzoyl. Y and Z can also be the O atom of an epoxide, or form one of the CC bonds of a C = C double bond.
0005So you can selectively the 12.13 double bond<ul id="ul0003" list-style="dash" compact="compact"><li>hydrogenate, for example catalytically or with diimine, giving a compound of formula 1 with Y = Z = H; or</li><li>epoxidize, for example with dimethyldioxirane or a peracid, whereby a compound of <b>formula 1</b> with Y with Z = -O-; or</li><li>convert to the dihalides, dipseudohalides or diazides, using a compound of <b>formula 1</b> with Y and Z = Hal, pseudo-hal or N<sub>3</sub> receives.</li></ul>
Manufacture and means
0006Finally, the invention relates to a therapeutic agent, in particular for use as a cytostatic agent, consisting of epothilone D or epothilone D in addition to one or more conventional carriers and / or diluents.
0007The invention is explained in more detail below by the description of some selected exemplary embodiments.
Examples
Example 1:
Epothilon D
A. Production strain and culture conditions according to the Epothilon basic patent DE-B-41 38 042.
B. Production with DSM 6773
000875 Culture is grown as described in the basic patent and inoculated with a production fermenter with 700 l production medium made from 0.8% starch, 0.2% glucose, 0.2% soy flour, 0.2% yeast extract, 0.1% CaCl<sub>2</sub> x 2H<sub>2</sub>0.1% MgSO4<sub>4</sub> x 7H<sub>2</sub>0.8 mg / l Fe-EDTA, pH = 7.4 and optionally 15 l adsorber resin Amberlite® XAD-16 used. The fermentation takes 7-10 days at 30 C, aeration with 0.1 NL / m<sup>3</sup>. By regulating the speed, the pO<sub>2</sub> kept at 30%.
C. Isolation
0009The adsorber resin is with a 0.7 m<sup>2</sup>, 100 mesh process filter separated from the culture and freed from polar accompanying substances by washing with 3 bed volumes of water / methanol 2: 1. A crude extract is obtained by elution with 4 bed volumes of methanol. Vac. is evaporated until the water phase occurs.
0010This is extracted three times with the same volume of ethyl acetate. Evaporation of the organic phase gives 240 g of crude extract, which is distributed between methanol and heptane in order to separate lipophilic accompanying substances. From the methanol phase i. Vak 180 g of raffinate obtained, which is fractionated in three portions over Sephadex® LH-20 (column 20 x 100 cm, 20 ml / min methanol). The epothilones are contained in the fraction of a total of 72 g eluted with a retention time of 240-300 min. To separate the epothilones, chromatography is carried out in three portions on Lichrosorb® RP-18 (15 µm, column 10 x 40 cm, eluent 180 ml / min methanol / water 65:35). After epothilone A and B, R<sub>t</sub> = 90-95 min epothilone C and 100-110 min epothilone D eluted and after evaporation i. Vac. Obtained in a yield of 0.3 g each as colorless oils.
D. Physical properties
0011<chemistry id="chem0003" num="0003"><img file="EP0941227B2_D0003.tif" /></chemistry>
Epothilon DR = CH
3
Epothilon D
0012C.<sub>27</sub>H<sub>41</sub>NO<sub>5</sub>S [491] ESI-MS: (positive ions): 492.5 for [M + H]<sup>+</sup>1H and 13C see NMR table<ul id="ul0004" list-style="none" compact="compact"><li>DC: R<sub>f</sub> = 0,82</li><li>TLC aluminum foil 60 F 254 Merck, mobile solvent: dichloromethane / methanol = 9: 1</li><li>Detection: UV quenching at 254 nm. Spray on with vanillin-sulfuric acid reagent, blue-gray staining when heated to 120 ° C.</li><li>HPLC: R<sub>t</sub> = 15.3 min</li><li>Column: Nucleosil® 100 C-18 7µm, 125 x 4 mm</li><li>Mobile solvent: methanol / water = 65:35</li><li>Flow: 1ml / min</li><li>Detection: diode array</li></ul><tables id="tabl0001" num="0001"><table frame="all"><title>Table 1:</title><tgroup cols="4" rowsep="0"><colspec colnum="1" colname="col1" colwidth="25mm" /><colspec colnum="2" colname="col2" colwidth="26mm" /><colspec colnum="3" colname="col3" colwidth="25mm" /><colspec colnum="4" colname="col4" colwidth="27mm" /><thead valign="top"><row rowsep="1"><entry namest="col1" nameend="col4" align="center"><b><sup>1</sup>Dog <sup>13</sup>C-NMR data of epothilone D in [D<sub>6</sub>] DMSO at 300 MHz</b></entry></row><row rowsep="1"><entry rowsep="0" align="center">H atom</entry><entry namest="col2" nameend="col4" align="center">Epothilon D</entry></row><row rowsep="1"><entry align="center" /><entry align="center">δ (ppm)</entry><entry align="center">C atom</entry><entry align="center">δ (ppm)</entry></row></thead><tbody><row><entry /><entry /><entry>1</entry><entry align="char" char="." charoff="20">170.1</entry></row><row><entry align="center">2 ha</entry><entry align="char" char=".">2.35</entry><entry>2</entry><entry align="char" char="." charoff="20">39.0</entry></row><row><entry align="center">2-Hb</entry><entry align="char" char=".">2.38</entry><entry>3</entry><entry align="char" char="." charoff="20">70.8</entry></row><row><entry align="center">3-H</entry><entry align="char" char=".">4.10</entry><entry>4</entry><entry align="char" char="." charoff="20">53.2</entry></row><row><entry align="center">3-OH</entry><entry align="char" char=".">5.08</entry><entry>5</entry><entry align="char" char="." charoff="20">217.4</entry></row><row><entry align="center">6-H</entry><entry align="char" char=".">3.11</entry><entry>6</entry><entry align="char" char="." charoff="20">44.4</entry></row><row><entry align="center">7-H</entry><entry align="char" char=".">3.48</entry><entry>7</entry><entry align="char" char="." charoff="20">75.5</entry></row><row><entry align="center">7-OH</entry><entry align="char" char=".">4.46</entry><entry>8</entry><entry align="char" char="." charoff="20">36.3</entry></row><row><entry align="center">8-H</entry><entry align="char" char=".">1.29</entry><entry>9</entry><entry align="char" char="." charoff="20">29.9</entry></row><row><entry align="center">9 ha</entry><entry align="char" char=".">1.14</entry><entry>10</entry><entry align="char" char="." charoff="20">25.9</entry></row><row><entry align="center">9-Hb</entry><entry align="char" char=".">1.38</entry><entry>11</entry><entry align="char" char="." charoff="20">31.8*</entry></row><row><entry align="center">10 ha</entry><entry align="char" char=".">1.14*</entry><entry>12</entry><entry align="char" char="." charoff="20">138.3</entry></row><row><entry align="center">10-Hb</entry><entry align="char" char=".">1.35*</entry><entry>13</entry><entry align="char" char="." charoff="20">120.3</entry></row><row><entry align="center">11-ha</entry><entry align="char" char=".">1.75</entry><entry>14</entry><entry align="char" char="." charoff="20">31.6*</entry></row><row><entry align="center">11-Hb</entry><entry align="char" char=".">2.10</entry><entry>15</entry><entry align="char" char="." charoff="20">76.6</entry></row><row><entry align="center">12-H</entry><entry /><entry>16</entry><entry align="char" char="." charoff="20">137.2</entry></row><row><entry align="center">13-H</entry><entry align="char" char=".">5.08</entry><entry>17</entry><entry align="char" char="." charoff="20">119.2</entry></row><row><entry align="center">14 ha</entry><entry align="char" char=".">2.30</entry><entry>18</entry><entry align="char" char="." charoff="20">152.1</entry></row><row><entry align="center">14-Hb</entry><entry align="char" char=".">2.65</entry><entry>19</entry><entry align="char" char="." charoff="20">117.7</entry></row><row><entry align="center">15-H</entry><entry align="char" char=".">5.29</entry><entry>20</entry><entry align="char" char="." charoff="20">164.3</entry></row><row><entry align="center">17-H</entry><entry align="char" char=".">6.51</entry><entry>21</entry><entry align="char" char="." charoff="20">18.9</entry></row><row><entry align="center">19-H</entry><entry align="char" char=".">7.35</entry><entry>22</entry><entry align="char" char="." charoff="20">19.7</entry></row><row><entry align="center">21-H<sub>3</sub></entry><entry align="char" char=".">2.65</entry><entry>23</entry><entry align="char" char="." charoff="20">22.5</entry></row><row><entry align="center">22-H<sub>3</sub></entry><entry align="char" char=".">0.90</entry><entry>24</entry><entry align="char" char="." charoff="20">16.4</entry></row><row><entry align="center">23-H<sub>3</sub></entry><entry align="char" char=".">1.19</entry><entry>25</entry><entry align="char" char="." charoff="20">18.4</entry></row><row><entry align="center">24 HOURS<sub>3</sub></entry><entry align="char" char=".">1.07</entry><entry>26</entry><entry align="char" char="." charoff="20">22.9</entry></row><row><entry align="center">25-H<sub>3</sub></entry><entry align="char" char=".">0.91</entry><entry>27</entry><entry align="char" char="." charoff="20">14.1</entry></row><row><entry align="center">26-H<sub>3</sub></entry><entry align="char" char=".">1.63</entry><entry /><entry /></row><row rowsep="1"><entry align="center">27-H<sub>3</sub></entry><entry align="char" char=".">2.11</entry><entry /><entry /></row></tbody></tgroup><tgroup cols="4" colsep="0" rowsep="0"><colspec colnum="1" colname="col1" colwidth="25mm" /><colspec colnum="2" colname="col2" colwidth="26mm" /><colspec colnum="3" colname="col3" colwidth="25mm" /><colspec colnum="4" colname="col4" colwidth="27mm" /><tbody><row><entry namest="col1" nameend="col4" align="justify">* Interchangeable assignment</entry></row></tbody></tgroup></table></tables>
Example 2 and Comparative Examples 1 to 5:
0013The epothilone D and epothilones A, B, C, E and F according to the invention (comparative examples 1 to 5) were tested with cell cultures (table 2) and for polymerization promotion (table 3).<tables id="tabl0002" num="0002"><table frame="all"><title>Table 2:</title><tgroup cols="7" rowsep="0"><colspec colnum="1" colname="col1" colwidth="50mm" /><colspec colnum="2" colname="col2" colwidth="13mm" /><colspec colnum="3" colname="col3" colwidth="17mm" /><colspec colnum="4" colname="col4" colwidth="15mm" /><colspec colnum="5" colname="col5" colwidth="13mm" /><colspec colnum="6" colname="col6" colwidth="13mm" /><colspec colnum="7" colname="col7" colwidth="13mm" /><thead valign="top"><row rowsep="1"><entry namest="col1" nameend="col7" align="center"><b>Epothilone tests with cell cultures</b></entry></row><row rowsep="1"><entry>Epothilone</entry><entry>A 493</entry><entry>B 507 IC-50</entry><entry>C. 477 [ng / ml]</entry><entry>D 491</entry><entry>E 509</entry><entry>F 523</entry></row><row rowsep="1"><entry>Mouse fibroblasts L 929</entry><entry align="right">4</entry><entry align="right">1</entry><entry align="right">100</entry><entry align="right">20</entry><entry align="right">20</entry><entry align="center">1,5</entry></row><row rowsep="1"><entry>human tumor cell lines:</entry><entry /><entry /><entry /><entry /><entry /><entry /></row></thead><tbody><row><entry>HL-60 (leukemia)</entry><entry align="right">0.2</entry><entry align="right">0.2</entry><entry align="right">10</entry><entry align="right">3</entry><entry align="right">1</entry><entry align="char" char=",">0,3</entry></row><row><entry>K-562 (leukemia)</entry><entry align="right">0.3</entry><entry align="right">0.3</entry><entry align="right">20</entry><entry align="right">10</entry><entry align="right">2</entry><entry align="char" char=",">0,5</entry></row><row><entry>U-937 (lymphoma)</entry><entry align="right">0.2</entry><entry align="right">0.2</entry><entry align="right">10</entry><entry align="right">3</entry><entry align="right">1</entry><entry align="char" char=",">0,2</entry></row><row><entry>KB-3.1 (cervical cancer)</entry><entry align="right">1</entry><entry align="right">0.6</entry><entry align="right">20</entry><entry align="right">12</entry><entry align="right">5</entry><entry align="char" char=",">0,5</entry></row><row><entry>KB-V1 (cervical cancer multires</entry><entry align="right">0.3</entry><entry align="right">0.3</entry><entry align="right">15</entry><entry align="right">3</entry><entry align="right">5</entry><entry align="char" char=",">0,6</entry></row><row><entry>A-498 (renal carcinoma)</entry><entry align="right">-</entry><entry align="right">1.5</entry><entry align="right">150</entry><entry align="right">20</entry><entry align="right">20</entry><entry align="char" char=",">3</entry></row><row rowsep="1"><entry>A-549 (lung cancer)</entry><entry align="right">0.7</entry><entry align="right">0.1</entry><entry align="right">30</entry><entry align="right">10</entry><entry align="right">3</entry><entry align="char" char=",">0,1</entry></row></tbody></tgroup></table></tables><tables id="tabl0003" num="0003"><table frame="all"><title>Table 3:</title><tgroup cols="7" rowsep="0"><colspec colnum="1" colname="col1" colwidth="21mm" /><colspec colnum="2" colname="col2" colwidth="12mm" /><colspec colnum="3" colname="col3" colwidth="12mm" /><colspec colnum="4" colname="col4" colwidth="12mm" /><colspec colnum="5" colname="col5" colwidth="12mm" /><colspec colnum="6" colname="col6" colwidth="15mm" /><colspec colnum="7" colname="col7" colwidth="15mm" /><thead valign="top"><row rowsep="1"><entry namest="col1" nameend="col7" align="center"><b>Polymerization test with epothilones</b></entry></row></thead><tbody><row rowsep="1"><entry namest="col1" nameend="col7" align="justify">Parameters: time to half-maximum polymerization of the control</entry></row></tbody></tgroup><tgroup cols="7" rowsep="0"><colspec colnum="1" colname="col1" colwidth="21mm" /><colspec colnum="2" colname="col2" colwidth="12mm" /><colspec colnum="3" colname="col3" colwidth="12mm" /><colspec colnum="4" colname="col4" colwidth="12mm" /><colspec colnum="5" colname="col5" colwidth="12mm" /><colspec colnum="6" colname="col6" colwidth="15mm" /><colspec colnum="7" colname="col7" colwidth="15mm" /><thead valign="top"><row rowsep="1"><entry rowsep="0">Measurement:</entry><entry rowsep="0" align="center">w</entry><entry rowsep="0" align="center">x</entry><entry rowsep="0" align="center">y</entry><entry rowsep="0" align="center">e.g.</entry><entry align="center"><b>medium</b></entry><entry align="center"><b>medium</b></entry></row><row rowsep="1"><entry /><entry /><entry /><entry /><entry /><entry align="center"><b>[s]</b></entry><entry align="center"><b>[%]</b></entry></row></thead><tbody><row><entry>control</entry><entry align="right">200</entry><entry align="right">170</entry><entry align="right">180</entry><entry align="right">210</entry><entry align="right"><b>190</b></entry><entry align="right"><b>100</b></entry></row><row><entry>Epothilone A</entry><entry align="right">95</entry><entry align="right">60</entry><entry align="right">70</entry><entry align="right">70</entry><entry align="right"><b>74</b></entry><entry align="right"><b>39</b></entry></row><row><entry>Epothilon B</entry><entry /><entry align="right">23</entry><entry align="right">25</entry><entry align="right">30</entry><entry align="right"><b>26</b></entry><entry align="right"><b>14</b></entry></row><row><entry>Epothilon C</entry><entry align="right">125</entry><entry align="right">76</entry><entry align="right">95</entry><entry align="right">80</entry><entry align="right"><b>94</b></entry><entry align="right"><b>49</b></entry></row><row><entry>Epothilon D</entry><entry align="right">125</entry><entry align="right">73</entry><entry align="right">120</entry><entry /><entry align="right"><b>106</b></entry><entry align="right"><b>56</b></entry></row><row><entry>Epothilon E</entry><entry align="right">80</entry><entry align="right">60</entry><entry align="right">50</entry><entry align="right">45</entry><entry align="right"><b>59</b></entry><entry align="right"><b>31</b></entry></row><row rowsep="1"><entry>Epothilon F</entry><entry align="right">80</entry><entry align="right">40</entry><entry align="right">30</entry><entry align="right">50</entry><entry align="right"><b>50</b></entry><entry align="right"><b>26</b></entry></row></tbody></tgroup></table></tables>
Standard test with 0.9 mg tubulin / ml and 1 µM sample concentration
0014The polymerization test is an in vitro test with purified tubulin from pig brain. The evaluation is carried out photometrically. Polymerization-promoting substances such as the epothilones shorten the time until the half-maximum polymerization has taken place, ie the shorter the time, the more effective the compound. w, x, y and z are four independent experiments, the relative effectiveness is expressed in the last column in% of the control; again, the lowest values indicate the best effectiveness. The ranking corresponds almost exactly to that found in cell cultures.
6 sheets
Sheet 1 Sheet 2 Sheet 3 Sheet 4 Sheet 5 Sheet 6
Every citation, both ways
| Document | Relation | Office |
|---|---|---|
| WO9310121A | Cites | World Intellectual Property Organization (WIPO) |
| WO9719086A | Cites | World Intellectual Property Organization (WIPO) |
| WO9808849A | Cites | World Intellectual Property Organization (WIPO) |
| BALOG A. ET AL.: "Total synthesis of (-)-epothilone A" ANGEWANDTE CHEMIE, INTERNATIONAL EDITION IN ENGLISH, Bd. 35, Nr. 23/24, 3.Januar 1997, Seiten 2801-2803, XP002035359 | Non-patent | – |
| NICOLAOU K.C. ET AL.: "An approach to epothilones based on olefin metathesis" ANGEWANDTE CHEMIE, INTERNATIONAL EDITION IN ENGLISH, Bd. 35, Nr. 20, 4.November 1996, Seiten 2399-2401, XP002035372 | Non-patent | – |
69 members in 25 offices
Priority claims5
| Document | Office | Kind | Date |
|---|---|---|---|
| 19647580 | Germany | – | |
| 19647580 | Germany | A | |
| 19707506 | Germany | – | |
| 19707506 | Germany | A | |
| 9706442 | European Patent Office (EPO) | W |
Members69
| Document | Office | Kind | |
|---|---|---|---|
| CA2269118A1 | Canada | A1 | |
| WO9822461A1 | World Intellectual Property Organization (WIPO) | A1 | |
| AU5483798A | Australia | A | |
| NO992338D0 | Norway | D0 | |
| NO992338L | Norway | L | |
| ZA9710384B | South Africa | B | |
| CZ175099A3 | Czechia | A3 | |
| EP0941227A1 | European Patent Office (EPO) | A1 | |
| PL333435A1 | Poland | A1 | |
| CN1237970A | China | A | |
| BR9713363A | Brazil | A | |
| IL129558D0 | Israel | D0 | |
| HU0000497A2 | Hungary | A2 | |
| HUP0000497A2 | Hungary | A2 | |
| HK1022314A1 | Hong Kong, China | A1 | |
| KR20000053308A | Republic of Korea | A | |
| TW408119B | Taiwan Province of China | B | |
| NZ335383A | New Zealand | A | |
| JP2001504474A | Japan | A | |
| HU0000497A3 | Hungary | A3 | |
| HUP0000497A3 | Hungary | A3 | |
| IL129558A | Israel | A | |
| AU753546B2 | Australia | B2 | |
| RU2198173C2 | Russian Federation | C2 | |
| EP1367057A1 | European Patent Office (EPO) | A1 | |
| EP0941227B1 | European Patent Office (EPO) | B1 | |
| AT267197T | Austria | T | |
| ATE267197T1 | Austria | T1 | |
| DE59711647D1 | Germany | D1 | |
| DK0941227T3 | Denmark | T3 | |
| PT941227E | Portugal | E | |
| ES2221692T3 | Spain | T3 | |
| CN1196698C | China | C | |
| US2005090535A1 | United States of America | A1 | |
| EP0941227B9 | European Patent Office (EPO) | B9 | |
| ES2221692T4 | Spain | T4 | |
| NO319984B1 | Norway | B1 | |
| CN1680370A | China | A | |
| KR100538095B1 | Republic of Korea | B1 | |
| CZ296164B6 | Czechia | B6 | |
| US7067544B2 | United States of America | B2 | |
| CY2542B1 | Cyprus | B1 | |
| HK1083832A1 | Hong Kong, China | A1 | |
| US2006264482A1 | United States of America | A1 | |
| PL193229B1 | Poland | B1 | |
| CN100344627C | China | C | |
| DK0941227T4 | Denmark | T4 | |
| EP1367057B1 | European Patent Office (EPO) | B1 | |
| AT408612T | Austria | T | |
| ATE408612T1 | Austria | T1 | |
| DE59712968D1 | Germany | D1 | |
| US2008293784A1 | United States of America | A1 | |
| PT1367057E | Portugal | E | |
| DK1367057T3 | Denmark | T3 | |
| ES2312695T3 | Spain | T3 | |
| JP4274583B2 | Japan | B2 | |
| US2009247592A1 | United States of America | A1 | |
| DK0941227T5 | Denmark | T5 | |
| EP0941227B2This record | European Patent Office (EPO) | B2 | |
| US2009270466A1 | United States of America | A1 | |
| ES2221692T5 | Spain | T5 | |
| US7759375B2 | United States of America | B2 | |
| US7846952B2 | United States of America | B2 | |
| BR9713363B1 | Brazil | B1 | |
| US2011136185A1 | United States of America | A1 | |
| US8076490B2 | United States of America | B2 | |
| CA2269118C | Canada | C | |
| CZ303422B6 | Czechia | B6 | |
| HU229833B1 | Hungary | B1 |
84 legal events, as 14 offices reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | Office | |
|---|---|---|---|
| Ep patent expiredExpiredEUP | EUP | DK | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Announcement of lapse in spainLapsedFD2A | FD2A | ES | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Patent expired because of reaching the maximum lifetime of a patentExpiredMK | MK | BE | |
| ExpiryMK07 | MK07 | AT | |
| Ep patent has lapsedLapsedEUG | EUG | SE | |
| Patent expiredExpiredMK9A | MK9A | IE | |
| Patent expired after termination of 20 yearsExpiredPE20 | PE20 | GB | |
| Patent ceasedCeasedPL | PL | CH | |
| Patent expired because of reaching the maximum lifetime of a patentExpiredMK | MK | NL | |
| Expiry of rightR071 | R071 | DE | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Fee paymentPLFP | PLFP | FR | |
| Fee paymentPLFP | PLFP | FR | |
| Nl: receipt of modified translations in the netherlands language after an opposition procedureOppositionNLR3 | NLR3 | EP | |
| Ep patent validated in greeceEP | EP | GR | |
| Patent modifiedDC2A | DC2A | ES | |
| Nl: decision of oppositionOppositionNLR2 | NLR2 | EP | |
| Ep patent has been republished in amended form after opposition at epoOppositionRPEO | RPEO | SE | |
| Modification of the scope of the patentAUFRECHTERHALTUNG DES PATENTES IN GEAENDERTER FORMAEN | AEN | CH | |
| Patent maintained in amended form27A | 27A | EP | |
| Designated contracting statesAK | AK | EP | |
| Corrected translation of ep patentT5 | T5 | DK | |
| Patent maintained in amended formORIGINAL CODE: 0009272PUAH | PUAH | EP | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: PATENT MAINTAINED AS AMENDEDSTAA | STAA | EP | |
| Reply to examination report in opposition receivedOppositionORIGINAL CODE: EPIDOSNORE3PLBC | PLBC | EP | |
| Information related to despatch of examination report in opposition + time limit modifiedOppositionORIGINAL CODE: EPIDOSCORE2PLAH | PLAH | EP | |
| Examination report in opposition despatched + time limitOppositionORIGINAL CODE: EPIDOSNORE2PLAY | PLAY | EP | |
| Amended ep patent with danish claimsT4 | T4 | DK | |
| Name/firm changedPFA | PFA | CH | |
| Opposition withdrawnWithdrawnORIGINAL CODE: 0009264PLBP | PLBP | EP | |
| Reply of patent proprietor to notice(s) of opposition receivedOppositionORIGINAL CODE: EPIDOSNOBS3PLBB | PLBB | EP | |
| Information modified related to communication of a notice of opposition and request to file observations + time limitOppositionORIGINAL CODE: EPIDOSCOBS2PLAF | PLAF | EP | |
| Information modified related to communication of a notice of opposition and request to file observations + time limitOppositionORIGINAL CODE: EPIDOSCOBS2PLAF | PLAF | EP | |
| Gb: corrected translation (of claims) filed (gb section 80(3)/1977)GBCC | GBCC | EP | |
| Information modified related to communication of a notice of opposition and request to file observations + time limitOppositionORIGINAL CODE: EPIDOSCOBS2PLAF | PLAF | EP | |
| Nl: opposition has been filed with the epoOppositionNLR1 | NLR1 | EP | |
| Opposition filedOpposition26 | 26 | EP | |
| Notice of opposition and request to file observation + time limit sentOppositionORIGINAL CODE: EPIDOSNOBS2PLAX | PLAX | EP | |
| Opposition filedOppositionORIGINAL CODE: 0009260PLBI | PLBI | EP | |
| Examination of admissibility of opposition: information related to despatch of communication + time limit deletedOppositionORIGINAL CODE: EPIDOSDOPE2PLAQ | PLAQ | EP | |
| Unpublished change to opponent dataORIGINAL CODE: EPIDOS OPPOPLBQ | PLBQ | EP | |
| Definitive protectionFG2A | FG2A | ES | |
| Fr: translation filedET | ET | EP | |
| Gb: translation of ep patent filed (gb section 77(6)(a)/1977)GBT | GBT | EP | |
| Ep patent has been republished with a corrected swedish translationRPOT | RPOT | SE | |
| Translation is availableAVAILABILITY OF NATIONAL TRANSLATIONSC4A | SC4A | PT | |
| Ep patent validated in greeceEP | EP | GR | |
| Ep patent with danish claimsT3 | T3 | DK | |
| Corresponds to:REF | REF | EP | |
| European patents granted designating irelandGrantedGERMANFG4D | FG4D | IE | |
| European patent takes effect as a national patent in ch/liEP | EP | CH | |
| New agentNV | NV | CH | |
| Designated contracting statesAK | AK | EP | |
| European patent grantedGrantedNOT ENGLISHFG4D | FG4D | GB | |
| (expected) grantORIGINAL CODE: 0009210GRAA | GRAA | EP | |
| Grant fee paidORIGINAL CODE: EPIDOSNIGR3GRAS | GRAS | EP | |
| Title (correction)EPOTHILONE D, PRODUCTION PROCESS, AND ITS USE AS CYTOSTATIC AS WELL AS PHYTOSANITARY AGENTRTI1 | RTI1 | EP | |
| Title (correction)EPOTHILONE D, PRODUCTION PROCESS, AND ITS USE AS CYTOSTATIC AS WELL AS PHYTOSANITARY AGENTRTI1 | RTI1 | EP | |
| Despatch of communication of intention to grant a patentORIGINAL CODE: EPIDOSNIGR1GRAP | GRAP | EP | |
| Title (correction)EPOTHILONE D, PRODUCTION PROCESS, AND ITS USE AS CYTOSTATIC AS WELL AS PHYTOSANITARY AGENTRTI1 | RTI1 | EP | |
| First examination report despatched17Q | 17Q | EP | |
| Request for examination filed17P | 17P | EP | |
| Designated contracting statesAK | AK | EP | |
| Public reference made under article 153(3) epc to a published international application that has entered the european phaseORIGINAL CODE: 0009012PUAI | PUAI | EP |
Numbers
- Publication
- 0941227
- Application
- 979512332
Titles3
- German
- EPOTHILON D, DESSEN HERSTELLUNG UND DESSEN VERWENDUNG ALS CYTOSTATISCHES MITTEL BZW. ALS PFLANZENSCHUTZMITTEL
- English
- EPOTHILONE D, PRODUCTION PROCESS, AND ITS USE AS CYTOSTATIC AS WELL AS PHYTOSANITARY AGENT
- French
- EPOTHILONE D, MODE DE PREPARATION ET APPLICATION COMME AGENT CYTOSTATIQUE ET PHYTOSANITAIRE
Classification
- CPC, 10
- C07D417/06
- A01N43/78
- A01N43/90
- C07D493/04
- C12P17/167
- C12P17/181
- A61P35/00
- A61P35/04
- A61P43/00
- A01N63/20
- IPC, 15
- C07D417 06
- C07D493 04
- C12P17 08
- A01N43 78
- A61K31 425
- C07D313 00
- C07D303 00
- A01N43 90
- A01N63 02
- A61K31 427
- A61P35 00
- C12P1 04
- C12P17 16
- C12P17 18
- C12R1 01
Designated states18
- Contracting states, 18
- Austria
- Belgium
- Switzerland
- Germany
- Denmark
- Spain
- Finland
- France
- United Kingdom
- Greece
- Ireland
- Italy
- Liechtenstein
- Luxembourg
- Monaco
- Netherlands (Kingdom of the)
- Portugal
- Sweden
